Prosecution Insights
Last updated: November 04, 2026
Application No. 18/848,978

DRUG COATING MEDICAL INSTRUMENT, PREPARATION METHOD THEREFOR AND USE THEREOF, AND DRUG COATING AND USE THEREOF

Non-Final OA §102§112
Filed
Sep 20, 2024
Priority
Mar 21, 2022 — CN 202210276877.8 +1 more
Examiner
PROSSER, ALISSA J
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mitrassist Lifesciences Limited
OA Round
1 (Non-Final)
16%
Grant Probability
At Risk
1-2
OA Rounds
1y 4m
Est. Remaining
27%
With Interview

Examiner Intelligence

Grants only 16% of cases
16%
Career Allowance Rate
79 granted / 511 resolved
-44.5% vs TC avg
Moderate +11% lift
Without
With
+11.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
59 currently pending
Career history
573
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
44.5%
+4.5% vs TC avg
§102
10.5%
-29.5% vs TC avg
§112
27.8%
-12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 511 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-6 are under consideration. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-6, drawn to a macrolide coated medical device obtained by a circumscribed process in the reply filed on October 5, 2026 is acknowledged. Applicant’s election without traverse of the species drug balloon and rapamycin (sirolimus) reading on claims 1-6 is acknowledged. Claims 7-9, 13 and 14 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim. Claims 1-6 as filed on October 5, 2026 are pending and under consideration to the extent of the elected species, e.g., the species of carrier is “drug balloon” and the species of macrolide is “rapamycin”. Information Disclosure Statement The information disclosure statement (IDS) submitted on October 14, 2026 was considered. Specification The amendment filed September 20, 2024 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: the insertion of a sentence expanding the scope of the suspension from “usual” and expanding of the scope of the suspension to dispersants other than water (apparently contradicting the disclosure at paragraph [0053]). Applicant is required to cancel the new matter in the reply to this Office Action. Claim Objections Claims 2-4 and 6 are objected to because of the following informalities: Claims 2-4: “a mass ratio” is properly “the mass ratio” because antecedent basis is implicit. Claim 2: “2~100:100~6000” should presumably recite “2-100:100-6000” or “2 to 100 : 100 to 6000” or some variation thereof. Claim 3: “0.01~10:1” should presumably recite “0.01-10:1” or “0.01 to 10 : 1” or some variation thereof. Claim 4: “0.1~30:100~1000” should presumably recite “0.1-30:100-1000” or “0.1 to 30 : 100 to 1000” or some variation thereof. Claim 6: “80~1200” should presumably recite “80-1200” or “80 to 1000”, “0 to 100” should presumably recite “0-100” or “0 to 100”, and “0~300” should presumably recite “0-300” or “0 to 300” or some variation thereof. Appropriate correction is required. Priority Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-6 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1 recites the drug coat is mainly obtained by coating. It is unclear how the qualifier mainly impacts the scope of the claim. Claims 2-6 are included in this rejection because they depend from claim 1 and because they do not remedy the noted ambiguity. Claims 5 and 6 are also included in this rejection because they appear to recite a different process. Claim 2 recites preferably, the macrolide drug … and preferably, the carrier. The phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. Description of examples or preferences is properly set forth in the specification rather than the claims. See MPEP § 2173.05 (d). Claim 3 recites five clauses prefaced with preferably. The phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05 (d). Claim 4 recites two clauses prefaced with preferably. The phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05 (d). Claim 5 recites the drug coat is obtained by coating the coating liquid comprising the macrolide drug and the dispersant (which is the organic solvent), and an additive solution comprising water together. It is unclear what is meant by an additive solution comprising water together because the earlier limitation of claim 5 stating the dispersant is the organic solvent appears to omit the alternative recitation of water as set forth in claim 1. Claim 6 is included in this rejection because it depends from claim 5 and because it does not remedy the noted ambiguity. Claim 6 recites a clause prefaced with preferably. The phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05 (d). Claim 6 recites the additive solution is mainly made of. It is unclear how the qualifier mainly impacts the scope of the solution composition. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-6 are rejected under 35 U.S.C. 102(a)(1) and under 35 U.S.C. 102(a)(2) as being anticipated by Li et al. (WO 2022/174720 A1, published August 25, 2022, filed January 24, 2022, as evidenced by US 2024/0131311, of record). Applicant cannot rely upon the certified copy of the foreign priority application to overcome the rejection under 35 U.S.C. 102(a)(1) because a translation of said application has not been made of record in accordance with 37 CFR 1.55. When an English language translation of a non-English language foreign application is required, the translation must be that of the certified copy (of the foreign application as filed) submitted together with a statement that the translation of the certified copy is accurate. See MPEP §§ 215 and 216. Regarding claim 1 Li teaches a drug-loaded medical instrument (drug coat medical device) comprising a medical instrument body (carrier) and at least one drug coating, the main component of the drug coating comprising a macrolide drug (title; abstract; claims). The drug coating is attached to at least one side of the surface of the medical instrument body (partially or completely covering the carrier) (abstract; claim 1). The macrolide drug is selected from the group inclusive of rapamycin (claim 5; paragraph [0043]). The body is a drug-coated balloon (paragraph [0042]). Regarding the process by which the coating is mainly obtained, product-by-process claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. See MPEP 2113. However, Li further teaches a method for preparing the device comprising dispersing macrolide drug crystal powder in a solvent (dispersant), applying the suspension (coating liquid) onto a surface of the device, applying a supersaturated solution of the macrolide ono the surface, and drying (removal of the solvent is implicit) (claim 7). Solvents include pentane or/and hexane (organic) (claim 10). Li further exemplifies an embodiment of supersaturated solution comprising rapamycin, acetone, ethanol and water (dispersants) (Example 1, paragraph [0077]). Regarding claim 2 Regarding the concentration of the drug in the coating liquid, product-by-process claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. See MPEP 2113. However, Li further teaches concentrations from 4 mg/10 mL to 10 mg/10 mL (paragraph [0064]) or from 1 mg/mL to 100 mg/mL such as 20 mg / mL (encompasses ratios by weight as instantly claimed approximating the density between 1000 mg/mL (aqueous) to 700 mg/mL (organic), e.g., ratios of 20 to 1000 or 20 to 700) (paragraph [0063]). Regarding claim 3 Li teaches the drug coating further comprises inter alia an antioxidant inclusive of ascorbic acid (water-soluble) or/and vitamin E (fat-soluble) (claim 6). Regarding the ratio of the antioxidant to the drug, it is unclear whether the preferable embodiment is a claim limitation (see rejections under 35 USC 112(b) supra). However, Li exemplifies an embodiment of solution comprising 125 mg rapamycin and 15 mg dibutylhydroxytoluene (antioxidant) (ratio of 15:125 ~= 0.12:1) (Example 1, paragraph [0077]). Regarding the conditional limitation, it is unclear whether the preferable embodiment is a claim limitation and if it is a claim limitation Li is in possession of coating liquids comprising an organic solvent and coatings comprising antioxidants inclusive of vitamin E. Regarding claim 4 Li teaches the drug coating further comprises inter alia polyvinyl pyrrolidone (claim 6). Regarding the concentration of the antioxidant in the coating liquid, it is unclear whether the preferable embodiment is a claim limitation (see rejections under 35 USC 112(b) supra) and if it is a claim limitation product-by-process claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. See MPEP 2113. Regarding claim 5 Regarding the process by which the coating is mainly obtained, product-by-process claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. See MPEP 2113. Regarding claim 6 Li teaches the drug coating further comprises inter alia an antioxidant inclusive of ascorbic acid (water-soluble) or/and vitamin E (fat-soluble) or/and inter alia polyvinyl pyrrolidone (claim 6). Regarding the concentrations in the coating liquid, it is unclear whether the preferable embodiment is a claim limitation (see rejections under 35 USC 112(b) supra) and if it is a claim limitation product-by-process claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. See MPEP 2113. The above teachings therefore anticipate the claims. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Kangas et al. (US 2011/0015664) teaches nucleation of amorphous coatings applied to the surface of drug delivery balloons (title; abstract; claims). Kurosaki et al. (US 2020/0197674) teaches precipitation of water-insoluble drugs inclusive of rapamycin upon volatilization of the organic solvent and in the presence of water (title; abstract; claims; paragraph [0086]). Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALISSA PROSSER whose telephone number is (571)272-5164. The examiner can normally be reached M - Th, 10 am - 6 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, DAVID BLANCHARD can be reached on (571)272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALISSA PROSSER/ Examiner, Art Unit 1619 /BENNETT M CELSA/Primary Examiner, Art Unit 1600
Read full office action

Prosecution Timeline

Sep 20, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778879
Cosmetic composition comprising fermented product of Nuruk
4y 6m to grant Granted Nov 03, 2026
Patent 12778876
BIO-GEL COMPOSITION AND NAIL CARE SYSTEM
4y 5m to grant Granted Nov 03, 2026
Patent 12478570
Cosmetic Formulation
7m to grant Granted Nov 25, 2025
Patent 12390503
GINKGO BILOBA LEAVE EXTRACT CAPSULE AND PREPARATION METHOD THEREFOR
3y 12m to grant Granted Aug 19, 2025
Patent 12310358
Fighting Against Varroa Parasite in Beekeeping Using a Natural Formulation Comprising Essential Oils and Wood Vinegar
3y 1m to grant Granted May 27, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
16%
Grant Probability
27%
With Interview (+11.2%)
3y 5m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 511 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month